76 related articles for article (PubMed ID: 8900846)
21. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
22. [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
Wang WH; Li YX; Song YW; Jin J; Liu YP; Wang SL; Zhou LQ; Liu XF; Yu ZH; Han JZ
Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):218-21. PubMed ID: 16875611
[TBL] [Abstract][Full Text] [Related]
23. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
24. [Outcome of 70 patients diagnosed with Hodgkin's disease after first-line and salvage treatment: experience at one center].
Arranz R; Gil-Fernández JJ; Muñoz E; Acevedo A; Sobrino MP; Fernández-Rañada JM
Sangre (Barc); 1998 Jun; 43(3):179-84. PubMed ID: 9741222
[TBL] [Abstract][Full Text] [Related]
25. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
[TBL] [Abstract][Full Text] [Related]
26. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
[TBL] [Abstract][Full Text] [Related]
27. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of an intensive regimen: VEBEP plus involved-field radiotherapy in advanced Hodgkin's disease.
Viviani S; Bonfante V; Santoro A; Zanini M; Devizzi L; Di Russo AD; Soncini F; Villani F; Ragni G; Valagussa P; Bonadonna G
Cancer J Sci Am; 1999; 5(5):275-82. PubMed ID: 10526668
[TBL] [Abstract][Full Text] [Related]
29. Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.
Josting A; Nogová L; Franklin J; Glossmann JP; Eich HT; Sieber M; Schober T; Boettcher HD; Schulz U; Müller RP; Diehl V; Engert A
J Clin Oncol; 2005 Mar; 23(7):1522-9. PubMed ID: 15632410
[TBL] [Abstract][Full Text] [Related]
30. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
31. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease.
Hudson MM; Krasin M; Link MP; Donaldson SS; Billups C; Merchant TE; Kun L; Billet AL; Kaste S; Tarbell NJ; Howard S; Friedmann AM; Hurwitz CA; Young JA; Marcus KC; Rai S; Cowan T; Weinstein HJ
J Clin Oncol; 2004 Nov; 22(22):4541-50. PubMed ID: 15542805
[TBL] [Abstract][Full Text] [Related]
32. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
33. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy.
Federico M; Bellei M; Brice P; Brugiatelli M; Nagler A; Gisselbrecht C; Moretti L; Colombat P; Luminari S; Fabbiano F; Di Renzo N; Goldstone A; Carella AM;
J Clin Oncol; 2003 Jun; 21(12):2320-5. PubMed ID: 12805333
[TBL] [Abstract][Full Text] [Related]
34. [The chemotherapeutic treatment of advanced Hodgkin's disease].
Epelbaum R; Haim N; Ben-Shahar M; Valtuch I; Faraggi D; Sharabi-Nov A; Ben-Arie Y; Cohen Y
Harefuah; 2001 Apr; 140(4):311-5, 367. PubMed ID: 11303395
[TBL] [Abstract][Full Text] [Related]
35. Inhibin B is superior to FSH as a serum marker for spermatogenesis in men treated for Hodgkin's lymphoma with chemotherapy during childhood.
van Beek RD; Smit M; van den Heuvel-Eibrink MM; de Jong FH; Hakvoort-Cammel FG; van den Bos C; van den Berg H; Weber RF; Pieters R; de Muinck Keizer-Schrama SM
Hum Reprod; 2007 Dec; 22(12):3215-22. PubMed ID: 17981817
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of salvage radiotherapy in Hodgkin's lymphoma after chemotherapy failure.
Campbell B; Wirth A; Milner A; Di Iulio J; MacManus M; Ryan G
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1538-45. PubMed ID: 16125872
[TBL] [Abstract][Full Text] [Related]
37. [Hodgkin's disease in childhood: long term results].
Cramer P; Schaison G; Andrieu JM; Boiron M; Bernard J
Arch Fr Pediatr; 1982 Apr; 39(4):223-9. PubMed ID: 6896975
[TBL] [Abstract][Full Text] [Related]
38. Combined modality therapy in advanced Hodgkin's disease: a report on 218 patients with a median follow-up of eight years.
Anselmo AP; Cavalieri E; Enrici RM; Donato V; Pescarmona E; Biagini C; Mandelli F
Haematologica; 1998 Jul; 83(7):645-50. PubMed ID: 9718870
[TBL] [Abstract][Full Text] [Related]
39. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease.
Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK
Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767
[TBL] [Abstract][Full Text] [Related]
40. [Comments about use of polychemotherapy MOPP associated with radiotherapy in the treatment of early stages of Hodgkin's disease. Preliminary report of 58 patients (author's transl)].
Brun B; Alaoui Y; Kuentz M; Baillet F; Maylin C; Vernant JP; Reyes F; Rochant H; Pierquin B; Dreyfus B
Ann Med Interne (Paris); 1980; 131(4):239-43. PubMed ID: 7425449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
